Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567795 | 1.00 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13316003 | 1.00 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1325234 | 0.81 | TSHR (0.59) | KMT2AGPR84MPOHTR2AHTR2C | |
| SCHEMBL1325236 | 0.81 | TSHR (0.59) | KMT2AGPR84MPOHTR2AHTR2C | |
| SCHEMBL1855576 | 0.78 | MAPT (0.62) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL837741 | 0.76 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1854707 | 0.76 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL874981 | 0.76 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13333434 | 0.76 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3800701 | 0.74 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253592-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO LLC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3411034-B1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO INC (KY) | 2020-11-25 | — | — | EP | disclosed |
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | INVENTISBIO INC. (KY) | 2020-05-12 | — | — | US | disclosed |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2017136688-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO INC. (KY) | 2017-08-10 | — | — | WO | disclosed |
| US-7741361-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7635711-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1836166-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20060189646-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060154925-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154925-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | MEN1 832/4885KMT2A 4288/4885ALDH1A1 4020/4885 |
| US-20210253592-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | ESR1, ESRRA, ESR2 | MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885 |
| US-20060189646-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | MEN1 832/4885KMT2A 4288/4885ALDH1A1 4020/4885 |
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | ESR1, ESRRA, ESR2 | MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885 |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | ESR1, ESRRA, ESR2 | MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.